A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Clinical trial NCT07489495 · RECRUITING

Trial details

NCT number: NCT07489495
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Renal Cell

Start date: 2026-04-09
Primary completion: 2030-11-27
Enrollment: 758

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.